RenovoRx completes enrollment in phase III pancreatic cancer trial
RenovoRx (NASDAQ:RNXT) has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with patient enrollment closing on August 7th. The company anticipates trial completion by the first half of 2027, with initial topline data expected in the second half of …